Vessel plus最新文献_第10页

Diagnosis of cardiac murmurs in children 儿童心脏杂音的诊断

Vessel plus Pub Date : 2022-01-01 DOI: 10.20517/2574-1209.2021.105

P. Rao

引用次数: 1

Daily atrial fibrillation issues: the view-point of a practicing surgeon 日常房颤问题:一个执业外科医生的观点

Vessel plus Pub Date : 2022-01-01 DOI: 10.20517/2574-1209.2021.118

T. Bilfinger

引用次数: 0

Management of chronic type B aortic dissection 慢性B型主动脉夹层的处理

Vessel plus Pub Date : 2022-01-01 DOI: 10.20517/2574-1209.2021.125

J. Trahanas, O. Jarral, Chandler Long, G. Hughes, Frank W. Sellke

引用次数: 1

Disclosing the cardiomyopathic substrate within the heart muscles in amyloidosis by cardiac magnetic resonance: diagnostic and prognostic implications 通过心脏磁共振揭示淀粉样变性患者心肌内的心肌病底物:诊断和预后意义

Vessel plus Pub Date : 2022-01-01 DOI: 10.20517/2574-1209.2021.81

S. Pica, M. Lombardi

引用次数: 0

Reduced myocardial perfusion is common among subjects with ischemia and no obstructive coronary artery disease and heart failure with preserved ejection fraction: a report from the WISE-CVD continuation study. 心肌灌注减少在心肌缺血、无阻塞性冠状动脉疾病和射血分数保留型心力衰竭患者中很常见：WISE-CVD 持续研究报告。

Vessel plus Pub Date : 2022-01-01 Epub Date: 2022-03-05 DOI: 10.20517/2574-1209.2021.103

Haider Aldiwani, Michael D Nelson, Behzad Sharif, Janet Wei, T Jake Samuel, Nissi Suppogu, Odayme Quesada, Galen Cook-Wiens, Edward Gill, Lidia S Szczepaniak, Louise E J Thomson, Balaji Tamarappoo, Anum Asif, Chrisandra Shufelt, Daniel Berman, C Noel Bairey Merz

{"title":"Reduced myocardial perfusion is common among subjects with ischemia and no obstructive coronary artery disease and heart failure with preserved ejection fraction: a report from the WISE-CVD continuation study.","authors":"Haider Aldiwani, Michael D Nelson, Behzad Sharif, Janet Wei, T Jake Samuel, Nissi Suppogu, Odayme Quesada, Galen Cook-Wiens, Edward Gill, Lidia S Szczepaniak, Louise E J Thomson, Balaji Tamarappoo, Anum Asif, Chrisandra Shufelt, Daniel Berman, C Noel Bairey Merz","doi":"10.20517/2574-1209.2021.103","DOIUrl":"10.20517/2574-1209.2021.103","url":null,"abstract":"Aim: Women with evidence of ischemia and no obstructive coronary artery disease (INOCA) have an increased risk of major adverse cardiac events, including heart failure with preserved ejection fraction (HFpEF). To investigate potential links between INOCA and HFpEF, we examined pathophysiological findings present in both INOCA and HFpEF.Methods: We performed adenosine stress cardiac magnetic resonance imaging (CMRI) in 56 participants, including 35 women with suspected INOCA, 13 women with HFpEF, and 8 reference control women. Myocardial perfusion imaging was performed at rest and with vasodilator stress with intravenous adenosine. Myocardial perfusion reserve index was quantified as the ratio of the upslope of increase in myocardial contrast at stress vs. rest. All CMRI measures were quantified using CVI42 software (Circle Cardiovascular Imaging Inc). Statistical analysis was performed using linear regression models, Fisher's exact tests, ANOVA, or Kruskal-Wallis tests.Results: Age (P = 0.007), Body surface area (0.05) were higher in the HFpEF group. Left ventricular ejection fraction (P = 0.02) was lower among the INOCA and HFpEF groups than reference controls after age adjustment. In addition, there was a graded reduction in myocardial perfusion reserve index in HFpEF vs. INOCA vs. reference controls (1.5 ± 0.3, 1.8 ± 0.3, 1.9 ± 0.3, P = 0.02), which was attenuated with age-adjustment.Conclusion: Reduced myocardial perfusion reserve appears to be a common pathophysiologic feature in INOCA and HFpEF patients.","PeriodicalId":75299,"journal":{"name":"Vessel plus","volume":"6 ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278056/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10785179","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Amiodarone and postoperative atrial fibrillation 胺碘酮与术后房颤的关系

Vessel plus Pub Date : 2022-01-01 DOI: 10.20517/2574-1209.2021.115

Stephen D. Waterford, Lindsey M Prescher, Michal Ad, L. A. Santore, Cordell Spellman, N. Ad

引用次数: 0

Improving future postoperative atrial fibrillation care: a 30,000-foot viewpoint 改善未来的术后房颤护理:3万英尺的观点

Vessel plus Pub Date : 2022-01-01 DOI: 10.20517/2574-1209.2021.120

Daniel F Pardo, F. Grover, Jessica Y. Rove, A. Shroyer

{"title":"Improving future postoperative atrial fibrillation care: a 30,000-foot viewpoint","authors":"Daniel F Pardo, F. Grover, Jessica Y. Rove, A. Shroyer","doi":"10.20517/2574-1209.2021.120","DOIUrl":"https://doi.org/10.20517/2574-1209.2021.120","url":null,"abstract":"Aim: In the United States (US), post-operative atrial fibrillation (POAF) is the most common complication following cardiac surgery. In order to understand the opportunities to improve POAF patients’ care, this “30,000 foot” review evaluated the professional society POAF database/registry definitions and guideline recommendations. Methods: All US-based professional society organizations with an interventional cardiac database/registry and/or cardiac care guidelines were identified; from these, the POAF database definitions and guideline recommendations were evaluated using a content analysis approach. Results: The Society of Thoracic Surgeons (STS) POAF definition was the most frequently referenced definition (21% of key references). Only 50% (n = 5/10) US cardiac surgery databases/registries included any POAF definition; compared to STS, the other five definitions required substantially more detailed documentation. Across eight guidelines, three different types of POAF recommendations were found: risk assessment (n = 3); prevention (n = 7); and management (n = 8). As a common feature, the risk assessment strategies tended to focus on advanced age (n = 6). Beta-blockers (n = 5) and amiodarone (n = 6) were common prevention approaches. Uniformly, anti-coagulation was the only management strategy (n = 8) recommended, barring any contraindications. Conclusion: Across ten professional societies, 50% had no POAF definition; of the remaining five, no POAF definitional consistency was found. Across the eight US-based professional society POAF-related guidelines, only anticoagulation was uniformly recommended. Given these “big picture” findings, professional societies are urged to work collaboratively to harmonize these divergent POAF definitions and consolidate their evidence-based guideline recommendations to improve future POAF patients’ quality of care.","PeriodicalId":75299,"journal":{"name":"Vessel plus","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67654843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Heart transplantation in cardiac amyloidosis 心脏淀粉样变性的心脏移植

Vessel plus Pub Date : 2022-01-01 DOI: 10.20517/2574-1209.2021.126

C. Di Nora, S. Sponga, C. Nalli, M. Driussi, I. Vendramin, G. Benedetti, G. Guzzi, M. Imazio, U. Livi

引用次数: 0

Global variation in the incidence of new-onset postoperative atrial fibrillation after cardiac and non-cardiac surgery: a systematic review 心脏和非心脏手术后新发房颤发生率的全球变化:系统回顾

Vessel plus Pub Date : 2022-01-01 DOI: 10.20517/2574-1209.2021.146

Daniel F Pardo, A. L. Shroyer, T. Bilfinger

{"title":"Global variation in the incidence of new-onset postoperative atrial fibrillation after cardiac and non-cardiac surgery: a systematic review","authors":"Daniel F Pardo, A. L. Shroyer, T. Bilfinger","doi":"10.20517/2574-1209.2021.146","DOIUrl":"https://doi.org/10.20517/2574-1209.2021.146","url":null,"abstract":"Aim: In the US, postoperative atrial fibrillation (POAF) is the most common complication after cardiac surgery and a frequent complication after non-cardiac surgery, causing excess patient length of stay and costs. After a comprehensive review looking for validated statistically significant data sets, too few data, particularly from outside of the US and Europe, could be found to perform a conclusive analysis, but there is enough data for a well-informed, educated opinion. Methods: A systematic review analyzing 28 international and US studies of POAF hospital length of stay were identified; from this excess and % excess along with total patient length of stay were calculated, where excess patient length of stay is defined as the difference in post-operative stay between POAF and non-POAF patients in days. Geographic variabilities were calculated using chi-square analyses for US regions and international comparisons for a variety of surgical procedures with POAF. Results: Geographic variability analyses when corrected for total hospital stay showed a 325% longer excess patient length of stay (days) in the US vs. Europe (3.4 days vs. 0.8 days) for coronary artery bypass grafting (CABG). It also showed a 27.3% longer excess patient length of stay (days) in the US vs. Europe (4.2 days vs. 3.3 days) for lung resections. These were both statistically significant at P < 0.001. Conclusion: There appear to be substantial variations in POAF-related care practices worldwide. In all practice settings, POAF causes increased patient length of stay. Europeans appear to do better than the US in POAF patients’ length of stay for CABG but not for lung resections. POAF is a worldwide problem where international cooperation in research and development of best practice guidelines would be particularly fruitful.","PeriodicalId":75299,"journal":{"name":"Vessel plus","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67655138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Perspective on the development of a bioengineered patch to treat heart failure: rationale and proposed design of phase I clinical trial 生物工程贴片治疗心力衰竭的发展前景:I期临床试验的基本原理和建议设计

Vessel plus Pub Date : 2022-01-01 DOI: 10.20517/2574-1209.2021.149

S. Goldman, J. Traverse, M. Zile, E. Juneman, B. Greenberg, R. Kelly, Jennifer W. Koevary, J. Lancaster

{"title":"Perspective on the development of a bioengineered patch to treat heart failure: rationale and proposed design of phase I clinical trial","authors":"S. Goldman, J. Traverse, M. Zile, E. Juneman, B. Greenberg, R. Kelly, Jennifer W. Koevary, J. Lancaster","doi":"10.20517/2574-1209.2021.149","DOIUrl":"https://doi.org/10.20517/2574-1209.2021.149","url":null,"abstract":"This perspective focuses on the development of tissue engineered (TE) cell-based therapies to treat left ventricular (LV) dysfunction and chronic heart failure (CHF). The development of induced pluripotent stem cells enabled investigators to seed or co-culture human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) alone and in combination with other cells onto bioengineered scaffolds applied to the epicardial surface of the damaged left ventricle. Using our work as an example, we show how a xenograft implant of a bioengineered scaffold embedded with human neonatal fibroblasts and seeded with hiPSC-CMs partially reversed maladaptive LV remodeling and improved LV systolic/diastolic function in an immune-competent rat model of CHF. The fibroblasts lay down an extracellular matrix and secrete growth factors that increase myocardial blood flow. This approach provides an improved cell payload that covers a larger area of the damaged left ventricle as opposed to direct cell injections into the heart or down the coronary arteries. These studies combined with ongoing studies in immune-competent Yucatan mini swine treated with the same xenograft led to the preliminary design of a proposed Phase I clinical trial that will be presented to the Federal Drug Administration. For the proposed Phase I clinical, this TE patch will be implanted onto the epicardial surface of non-immunosuppressed patients undergoing elective Coronary Artery Bypass Grafting with Ejection Fractions ≥ 20% and ≤ 45%. The primary endpoints will be adverse events/severe adverse events associated with placing the TE patch on the heart. While Phase I trials are primarily safety trials, this proposed trial is designed to obtain some potential efficacy endpoints to help with the design of future Phase II/III clinical trials. These endpoints include changes in LV remodeling that were seen in the pre-clinical animal models as well as including endpoints that focus on patient well-being.","PeriodicalId":75299,"journal":{"name":"Vessel plus","volume":"1 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67655150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1